Published in Science on November 13, 2014
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature (2015) 2.15
Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell (2015) 1.96
Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. Cancer Discov (2015) 1.60
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med (2017) 1.49
Super-Enhancer-Mediated RNA Processing Revealed by Integrative MicroRNA Network Analysis. Cell (2017) 1.43
TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat Genet (2017) 1.43
Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nat Biotechnol (2016) 1.36
CTCF/cohesin-binding sites are frequently mutated in cancer. Nat Genet (2015) 1.36
Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer (2015) 1.32
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood (2015) 1.19
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet (2016) 1.13
Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet (2015) 1.10
Role of non-coding sequence variants in cancer. Nat Rev Genet (2016) 1.10
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
Non-coding Transcription Instructs Chromatin Folding and Compartmentalization to Dictate Enhancer-Promoter Communication and T Cell Fate. Cell (2017) 1.06
An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet (2016) 1.06
dbSUPER: a database of super-enhancers in mouse and human genome. Nucleic Acids Res (2015) 1.02
The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell (2016) 0.98
Hierarchy within the mammary STAT5-driven Wap super-enhancer. Nat Genet (2016) 0.97
Cancer whole-genome sequencing: present and future. Oncogene (2015) 0.95
Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer. Genome Biol (2016) 0.92
Dynamic Control of Enhancer Repertoires Drives Lineage and Stage-Specific Transcription during Hematopoiesis. Dev Cell (2016) 0.92
CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest (2016) 0.92
Functional validation of mouse tyrosinase non-coding regulatory DNA elements by CRISPR-Cas9-mediated mutagenesis. Nucleic Acids Res (2015) 0.92
Bivalent Regions of Cytosine Methylation and H3K27 Acetylation Suggest an Active Role for DNA Methylation at Enhancers. Mol Cell (2016) 0.91
INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma. Genes Dev (2016) 0.91
The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Mol Med (2016) 0.91
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Mol Cell (2015) 0.91
Enabling functional genomics with genome engineering. Genome Res (2015) 0.90
Identification of High-Impact cis-Regulatory Mutations Using Transcription Factor Specific Random Forest Models. PLoS Comput Biol (2015) 0.90
SEA: a super-enhancer archive. Nucleic Acids Res (2015) 0.89
The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet (2016) 0.89
The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis. Front Oncol (2015) 0.89
Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nat Genet (2016) 0.89
Signatures of accelerated somatic evolution in gene promoters in multiple cancer types. Nucleic Acids Res (2015) 0.89
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open (2016) 0.88
A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets. Oncotarget (2014) 0.88
Directly targeting transcriptional dysregulation in cancer. Nat Rev Cancer (2015) 0.87
BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. Cell Rep (2016) 0.85
Single-cell transcriptional analysis of normal, aberrant, and malignant hematopoiesis in zebrafish. J Exp Med (2016) 0.85
Motif signatures in stretch enhancers are enriched for disease-associated genetic variants. Epigenetics Chromatin (2015) 0.85
An epigenetic gateway to brain tumor cell identity. Nat Neurosci (2015) 0.85
The role of enhancers in cancer. Nat Rev Cancer (2016) 0.84
The biology of pediatric acute megakaryoblastic leukemia. Blood (2015) 0.84
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol (2016) 0.83
Super Enhancers in Cancers, Complex Disease, and Developmental Disorders. Genes (Basel) (2015) 0.83
Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. Epigenetics (2015) 0.83
Models of human core transcriptional regulatory circuitries. Genome Res (2016) 0.83
Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Nat Commun (2016) 0.82
Regulation of disease-associated gene expression in the 3D genome. Nat Rev Mol Cell Biol (2016) 0.80
c-Myb Binding Sites in Haematopoietic Chromatin Landscapes. PLoS One (2015) 0.79
Position effects influence HIV latency reversal. Nat Struct Mol Biol (2016) 0.79
Emerging concepts of epigenetic dysregulation in hematological malignancies. Nat Immunol (2016) 0.79
The genetics and molecular biology of T-ALL. Blood (2017) 0.78
Frequent DPH3 promoter mutations in skin cancers. Oncotarget (2015) 0.78
Archaic Adaptive Introgression in TBX15/WARS2. Mol Biol Evol (2017) 0.78
The search for cis-regulatory driver mutations in cancer genomes. Oncotarget (2015) 0.78
microRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia. Oncotarget (2016) 0.78
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat Commun (2017) 0.78
Genetic Basis of Acute Lymphoblastic Leukemia. J Clin Oncol (2017) 0.78
Lingering Questions about Enhancer RNA and Enhancer Transcription-Coupled Genomic Instability. Trends Genet (2017) 0.77
Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med (2017) 0.77
Tissue-specific tumorigenesis: context matters. Nat Rev Cancer (2017) 0.77
APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia (2017) 0.77
Epigenetics of hematopoiesis and hematological malignancies. Genes Dev (2016) 0.77
An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells. Leukemia (2016) 0.77
Genome-wide repression of eRNA and target gene loci by the ETV6-RUNX1 fusion in acute leukemia. Genome Res (2016) 0.77
Cross-species oncogenomics using zebrafish models of cancer. Curr Opin Genet Dev (2015) 0.77
PEDLA: predicting enhancers with a deep learning-based algorithmic framework. Sci Rep (2016) 0.77
Cancer. Cancer by super-enhancer. Science (2014) 0.77
Combinatorial bZIP dimers display complex DNA-binding specificity landscapes. Elife (2017) 0.77
Enhancer deregulation in cancer and other diseases. Bioessays (2016) 0.76
Enhancer scanning to locate regulatory regions in genomic loci. Nat Protoc (2015) 0.76
High-density P300 enhancers control cell state transitions. BMC Genomics (2015) 0.76
TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia. Leukemia (2015) 0.76
Applying CRISPR-Cas9 tools to identify and characterize transcriptional enhancers. Nat Rev Mol Cell Biol (2016) 0.76
Brachyury, Foxa2 and the cis-Regulatory Origins of the Notochord. PLoS Genet (2015) 0.76
Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis. PLoS One (2016) 0.76
Epstein-Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation. Proc Natl Acad Sci U S A (2016) 0.76
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet (2017) 0.75
Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Leukemia (2016) 0.75
Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood (2017) 0.75
Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nat Commun (2017) 0.75
Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage. Leukemia (2016) 0.75
Limb girdle myasthenia with digenic RAPSN and a novel disease gene AK9 mutations. Eur J Hum Genet (2016) 0.75
Mapping regulatory elements. Nat Biotechnol (2016) 0.75
Inducible super-enhancers are organized based on canonical signal-specific transcription factor binding elements. Nucleic Acids Res (2017) 0.75
cis-Regulatory Circuits Regulating NEK6 Kinase Overexpression in Transformed B Cells Are Super-Enhancer Independent. Cell Rep (2017) 0.75
Barcelona conference on epigenetics and cancer 2016 - beyond cancer genomes. Epigenetics (2017) 0.75
Elucidating the mechanisms of transcription regulation during heart development by next-generation sequencing. J Hum Genet (2015) 0.75
Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet (2017) 0.75
Functional Enhancers As Master Regulators of Tissue-Specific Gene Regulation and Cancer Development. Mol Cells (2017) 0.75
"PEAR-ing" Genomic and Epigenomic Analyses for Cancer Gene Discovery. Cancer Discov (2015) 0.75
Transcriptional Dynamics at Brain Enhancers: from Functional Specialization to Neurodegeneration. Curr Neurol Neurosci Rep (2016) 0.75
Comparative analyses of super-enhancers reveal conserved elements in vertebrate genomes. Genome Res (2016) 0.75
Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. Cancer Discov (2016) 0.75
PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet (2017) 0.75
Quantitative Trait Loci Identify Functional Noncoding Variation in Cancer. PLoS Genet (2016) 0.75
Striatal H3K27 Acetylation Linked to Glutamatergic Gene Dysregulation in Human Heroin Abusers Holds Promise as Therapeutic Target. Biol Psychiatry (2016) 0.75
UniPROBE: an online database of protein binding microarray data on protein-DNA interactions. Nucleic Acids Res (2008) 6.83
Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med (1993) 2.23
Transcription factor trapping by RNA in gene regulatory elements. Science (2015) 1.24
The developmental potential of iPSCs is greatly influenced by reprogramming factor selection. Cell Stem Cell (2014) 1.13
The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med (2017) 0.76
Genome-wide Trans-ethnic Meta-analysis Identifies Seven Genetic Loci Influencing Erythrocyte Traits and a Role for RBPMS in Erythropoiesis. Am J Hum Genet (2016) 0.75
YY1 Is a Structural Regulator of Enhancer-Promoter Loops. Cell (2017) 0.75
Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Rep (2017) 0.75